5 months ago
ZVRA
AnalystsEddie HickmanEddie Hickman's Stock Forecasts
AnalystsEddie Hickman
Sectors:
Industries:
Analyst Ranking
Top 27%
#1346 out of 4995 analysts
Average Return
+25.34%
Win Rate
69%9 out of 13
Risk vs Reward
Poor
Good
Eddie Hickman's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Iveric Bio IncISEE | +167.40% | $14.94 | $39.95 | 2022-09-07 - 2023-07-10 | Strong Buy |
Tarsus Pharmaceuticals IncTARS | +85.16% | $16.98 | $31.44 | 2023-09-11 - 2024-09-10 | Strong Buy |
Tarsus Pharmaceuticals IncTARS | +67.37% | $18.51 | $30.98 | 2023-06-16 - 2024-06-14 | Strong Buy |
Tarsus Pharmaceuticals IncTARS | +57.10% | $16.83 | $26.44 | 2023-08-14 - 2024-08-13 | Strong Buy |
Tarsus Pharmaceuticals IncTARS | +34.52% | $42.56 | $57.25 | 2025-02-26 - 2025-08-22 | Strong Buy |
Eddie Hickman Analyst Color
Get additional color on Eddie Hickman's coverage of popular stocks
Eddie Hickman's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Tarsus Pharmaceuticals IncTARS | 5 | Strong Buy | $84.00 | +46.72% | Maintains | 4 months ago |
Promis Neurosciences IncPMN | 1 | Strong Buy | $6.00 | +1,011.11% | Reiterates | 5 months ago |
Zevra Therapeutics IncZVRA | 1 | Strong Buy | $22.00 | +133.05% | Maintains | 5 months ago |
Gh Research PLCGHRS | 1 | Strong Buy | $32.00 | +144.65% | Initiates Coverage On | 5 months ago |
Cybin IncCYBN | 1 | Strong Buy | $35.00 | +389.51% | Initiates Coverage On | 5 months ago |
Outlook Therapeutics IncOTLK | 3 | Strong Buy | $12.00 | +347.76% | Reiterates | 7 months ago |
Iveric Bio IncISEE | 1 | Strong Buy | $35.00 | N/A | Maintains | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.